MCID: ANL017
MIFTS: 45

Anal Squamous Cell Carcinoma malady

Categories: Gastrointestinal diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 10 12 65
Epidermoid Anal Carcinoma 10
 
Carcinoma of Anal Margin 65

Classifications:



External Ids:

Disease Ontology10 DOID:5525
SNOMED-CT59 255084004
NCIt42 C9161
UMLS65 C1412036

Summaries for Anal Squamous Cell Carcinoma

About this section
Disease Ontology:10 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary: Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to spinal cord astrocytoma and deep leiomyoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A), and among its related pathways are Cell cycle Role of 14-3-3 proteins in cell cycle regulation and Regulation of TP53 Activity through Acetylation. Affiliated tissues include breast, kidney and liver, and related mouse phenotype tumorigenesis.

Related Diseases for Anal Squamous Cell Carcinoma

About this section

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 129)
idRelated DiseaseScoreTop Affiliating Genes
1spinal cord astrocytoma10.6CDKN2A, TP53
2deep leiomyoma10.6CDKN2A, TP53
3splenogonadal fusion limb defects micrognatia10.6CDKN2A, TP53
4basaloid squamous cell carcinoma10.6CDKN2A, TP53
5chronic rhinitis10.6CDKN2A, TP53
6myotonia congenita10.5CDKN2A, TP53
7anal paget's disease10.5CDKN2A, TP53
8renal pelvis squamous cell carcinoma10.5CDKN2A, TP53
9hepatopulmonary syndrome10.5CDKN2A, TP53
10spastic ataxia 210.5CDKN2A, TP53
11peroxisomal disease10.5CDKN2A, TP53
12cervical verrucous carcinoma10.5CDKN2A, TP53
13apocrine adenocarcinoma10.5CDKN2A, TP53
14benign mesenchymoma10.5CDKN2A, TP53
15basophilic carcinoma10.5CDKN2A, TP53
16recessive dystrophic epidermolysis bullosa-generalized other10.5CDKN2A, TP53
17adenoid squamous cell carcinoma10.5CDKN2A, TP53
18gastrointestinal neuroendocrine tumor10.5CDKN2A, TP53
19acute pancreatitis10.5CDKN2A, TP53
20childhood pilocytic astrocytoma10.5CDKN2A, TP53
21progressive muscular atrophy10.5CDKN2A, TP53
22bilateral breast cancer10.5CDKN2A, TP53
23pancytopenia10.5CDKN2A, TP53
24gestational trophoblastic neoplasm10.5CDKN2A, TP53
25lymphatic system cancer10.5CDKN2A, TP53
26angiolipoma10.5CDKN2A, MDM2
27arteriosclerosis obliterans10.5AKT1, CDKN2A
28dental pulp necrosis10.4CDKN2A, TP53
29myxoid chondrosarcoma10.4CDKN2A, MDM2
30subglottic angioma10.4MDM2, TP53
31mixed liposarcoma10.4CDKN2A, MDM2
32ovary leiomyosarcoma10.4CDKN2A, MDM2
33spindle cell liposarcoma10.4MDM2, TP53
34herpes simplex10.4MDM2, TP53
35vascular dementia10.4CDKN2A, TP53
36chronic duodenal ileus10.4MDM2, TP53
37familial short qt syndrome10.4CDKN2A, TP53
38pulmonary immaturity10.4MDM2, TP53
39molluscum contagiosum10.4CDKN2A, TP53
40common bile duct disease10.4MDM2, TP53
41visual cortex disease10.4CDKN2A, MDM2
42connective tissue benign neoplasm10.4CDKN2A, TP53
43soft tissue sarcoma childhood10.4MDM2, TP53
44merrf syndrome10.4MDM2, TP53
45kidney benign neoplasm10.3AKT1, TP53
46sebaceous breast carcinoma10.3MDM2, TP53
47factitious disorder10.3MDM2, TP53
48breast adenomyoepithelial adenosis10.3MDM2, TP53
49papillary adenocarcinoma10.3AKT1, TP53
50fibrosarcoma10.3CDKN2A, MDM2

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to anal squamous cell carcinoma

Symptoms for Anal Squamous Cell Carcinoma

About this section

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

About this section

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 77)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Imiquimodapproved, investigationalPhase 4, Phase 313199011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
I06-0624
 
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
Vyloma
ZINC19632912
Zartra
Zyclara
imiquimod
2Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
3Adjuvants, ImmunologicPhase 4, Phase 3, Phase 11783
4interferonsPhase 4, Phase 31930
5
CisplatinapprovedPhase 3, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6
FluorouracilapprovedPhase 3, Phase 2, Phase 1, Phase 0168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
7
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
8
PaclitaxelapprovedPhase 3, Phase 2, Phase 1262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
9
Capecitabineapproved, investigationalPhase 3, Phase 21220154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
10NarcoticsPhase 32709
11Liver ExtractsPhase 3, Phase 2, Phase 13572
12Central Nervous System DepressantsPhase 310016
13Peripheral Nervous System AgentsPhase 3, Phase 218510
14Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 14294
15Tubulin ModulatorsPhase 3, Phase 2, Phase 14279
16Anesthetics, IntravenousPhase 31943
17Antimitotic AgentsPhase 3, Phase 2, Phase 14296
18Albumin-Bound PaclitaxelPhase 3, Phase 2, Phase 12621
19pancreatic polypeptidePhase 320
20Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 05770
21Immunosuppressive AgentsPhase 3, Phase 2, Phase 1, Phase 010422
22AntimetabolitesPhase 3, Phase 2, Phase 09454
23Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Phase 09140
24Alkylating AgentsPhase 3, Phase 2, Phase 03582
25Anesthetics, GeneralPhase 32274
26MitomycinsPhase 3, Phase 2, Phase 1, Phase 0219
27Antibiotics, AntitubercularPhase 3, Phase 2, Phase 05971
28Nucleic Acid Synthesis InhibitorsPhase 3, Phase 2, Phase 03836
29Analgesics, OpioidPhase 32304
30AnestheticsPhase 37385
31AnalgesicsPhase 39358
32ColaNutraceuticalPhase 3, Phase 2, Phase 11768
33
CetuximabapprovedPhase 2, Phase 1713205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
34
Oxaliplatinapproved, investigationalPhase 2132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
35
CarboplatinapprovedPhase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
36
NivolumabapprovedPhase 2, Phase 1198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
37PembrolizumabapprovedPhase 22881374853-91-4
38
Ritonavirapproved, investigationalPhase 2850155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
39
IndinavirapprovedPhase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir
40
SuccinylcholineapprovedPhase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
41
Docetaxelapproved, investigational, Approved May 1996Phase 2, Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
42Anti-Infective AgentsPhase 2, Phase 117220
43AntibodiesPhase 1, Phase 24477
44ImmunoglobulinsPhase 1, Phase 24477
45Antibodies, MonoclonalPhase 1, Phase 22413
46HIV Protease InhibitorsPhase 24558
47Cytochrome P-450 Enzyme InhibitorsPhase 23036
48Protease InhibitorsPhase 24558
49Immunoglobulin GPhase 2146
50taxanePhase 2324

Interventional clinical trials:

(show top 50)    (show all 55)
idNameStatusNCT IDPhase
1Anal Dysplasia Study of Men Who Have Sex With Men Living With HIVWithdrawnNCT01663558Phase 4
2Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00003596Phase 3
3Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal CancerCompletedNCT00025090Phase 3
4Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
5Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard RadiochemotherapyRecruitingNCT02369939Phase 3
6Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-PositiveRecruitingNCT02059499Phase 3
7Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerActive, not recruitingNCT00003652Phase 3
8Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma PatientsNot yet recruitingNCT02526953Phase 3
9Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal CancerTerminatedNCT00068744Phase 2, Phase 3
10Oral Rigosertib for Squamous Cell CarcinomaCompletedNCT01807546Phase 2
11Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00093379Phase 2
12A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.CompletedNCT01941966Phase 2
13Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the AnusRecruitingNCT01581840Phase 1, Phase 2
14International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly PaclitaxelRecruitingNCT02051868Phase 2
15Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV InfectionRecruitingNCT02437851Phase 2
16Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal CarcinomaRecruitingNCT02402842Phase 2
17Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal CancerRecruitingNCT02560298Phase 2
18Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal CancerRecruitingNCT00316888Phase 2
19Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)RecruitingNCT02628067Phase 2
20External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesRecruitingNCT00637637Phase 2
21Genetic Predictors of Benefit to PembrolizumabRecruitingNCT02710396Phase 2
22Vectibix for the Treatment of Anal CancerActive, not recruitingNCT01285778Phase 2
23Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal CancerActive, not recruitingNCT00324415Phase 2
24Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal CanalActive, not recruitingNCT02314169Phase 2
25Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal CancerActive, not recruitingNCT00423293Phase 2
26Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal CancerActive, not recruitingNCT00955240Phase 2
27Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the RectumActive, not recruitingNCT02399813Phase 1, Phase 2
28Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By SurgeryActive, not recruitingNCT00331760Phase 2
29Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal CanalTerminatedNCT01843452Phase 2
30Nimotuzumab With Radiotherapy in the Treatment of Anal Canal CancersTerminatedNCT01382745Phase 2
31A Phase 1 Study in Participants With Advanced CancerCompletedNCT01115790Phase 1
32Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.CompletedNCT00423254Phase 1
33Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
34Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
357-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
36Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
37Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
38MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
39Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
40Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid TumorsRecruitingNCT02408861Phase 1
41HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIARecruitingNCT02379520Phase 1
42Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionRecruitingNCT01249443Phase 1
43Molecular Biology of Anal Cancer in HIV-Positive PatientsCompletedNCT00952874
44OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With CancerCompletedNCT00900302
45Videoscopic Versus Open Inguinal Lymphadenectomy for CancerCompletedNCT01526486
46ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapyRecruitingNCT02145416
47Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of PatientsRecruitingNCT01877135
48Prevalence of Anal Dysplasia and Cancer in WomenRecruitingNCT02140021
49Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal CarcinomaRecruitingNCT01858025Phase 0
50Anal Dysplasia in Patients With Inflammatory Bowel DiseaseRecruitingNCT01653054

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

About this section

Anatomical Context for Anal Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

33
Breast, Kidney, Liver, Lung, Skin, Lymph node, Ovary

Animal Models for Anal Squamous Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.7AKT1, CDKN2A, MDM2, TP53

Publications for Anal Squamous Cell Carcinoma

About this section

Articles related to Anal Squamous Cell Carcinoma:

(show top 50)    (show all 68)
idTitleAuthorsYear
1
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. (25984929)
2016
2
Chemoradiotherapy for anal squamous cell carcinoma. (27118047)
2016
3
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. (26961789)
2016
4
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. (27125703)
2016
5
A tumor control probability model for anal squamous cell carcinoma. (26243680)
2015
6
Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. (26678214)
2015
7
Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil? (25987898)
2015
8
High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. (25702585)
2015
9
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. (25810165)
2015
10
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. (24839133)
2015
11
Anal squamous cell carcinoma: an evolution in disease and management. (25278699)
2014
12
Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review. (26753381)
2014
13
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma. (23958077)
2013
14
Outcome of salvage surgery for anal squamous cell carcinoma. (23522325)
2013
15
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection. (23893826)
2013
16
A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. (24050823)
2013
17
Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma. (23872032)
2013
18
Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals. (24242676)
2013
19
Development of cerebral metastasis after medical and surgical treatment of anal squamous cell carcinoma. (23091760)
2012
20
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. (22717459)
2012
21
Evaluation of Langerhans cells counts comparing HIV-positive and negative anal squamous cell-carcinoma patients. (23033134)
2012
22
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. (25031942)
2012
23
Current treatment of anal squamous cell carcinoma. (23116582)
2012
24
Metachronous splenic metastasis in an anal squamous cell carcinoma. (21563664)
2011
25
The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. (21128253)
2011
26
The role of A^a8,fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma. (20070338)
2011
27
Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. (20181236)
2010
28
Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. (19960431)
2010
29
Current therapeutic strategies for anal squamous cell carcinoma in Japan. (19856049)
2009
30
Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. (18066626)
2008
31
Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. (18194582)
2008
32
Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. (17721920)
2007
33
Letter to the editor concerning "HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN)" by Varnai et al. (Int J Colorectal Dis 21:135-142, 2006). (16703315)
2007
34
Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. (17255774)
2007
35
Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous cell carcinoma patients. (18214063)
2007
36
Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. (16299038)
2006
37
HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. (15864603)
2006
38
Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. (16998682)
2006
39
DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. (16166431)
2005
40
Angiogenesis in anal warts, anal intraepithelial neoplasia and anal squamous cell carcinoma. (12814415)
2003
41
Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. (14695153)
2003
42
Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. (11330577)
2001
43
Loss of heterozygosity and HIV infection in patients with anal squamous-cell carcinoma. (11598481)
2001
44
Anal squamous cell carcinoma in a patient with Peutz-Jeghers syndrome. (11281174)
2001
45
An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy. (8441261)
1993
46
Nucleolar organiser regions (AgNORS) in anal intraepithelial neoplasia and invasive anal squamous cell carcinoma. (1430259)
1992
47
In situ hybridization analysis of human papillomavirus in anal squamous cell carcinoma. (2554279)
1989
48
Anal squamous cell carcinoma arising on radio-dermatitis cured with chemotherapy alone: case report. (3660479)
1987
49
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. (3768879)
1986
50
CERVICAL CARCINOMA IN SITU AND ANAL SQUAMOUS-CELL CARCINOMA FOLLOWING RADIATION THERAPY FOR SQUAMOUS-CELL CARCINOMA OF CERVIX. (14069947)
1963

Variations for Anal Squamous Cell Carcinoma

About this section

Expression for genes affiliated with Anal Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for genes affiliated with Anal Squamous Cell Carcinoma

About this section

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 45)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.6AKT1, TP53
29.6AKT1, TP53
39.5MDM2, TP53
4
Show member pathways
9.5MDM2, TP53
59.2AKT1, CDKN2A, TP53
69.2CDKN2A, MDM2, TP53
7
Show member pathways
9.2CDKN2A, MDM2, TP53
89.2CDKN2A, MDM2, TP53
99.2CDKN2A, MDM2, TP53
109.2CDKN2A, MDM2, TP53
119.2CDKN2A, MDM2, TP53
129.2CDKN2A, MDM2, TP53
13
Show member pathways
9.2CDKN2A, MDM2, TP53
149.2CDKN2A, MDM2, TP53
15
Show member pathways
9.2CDKN2A, MDM2, TP53
169.2CDKN2A, MDM2, TP53
17
Show member pathways
9.1AKT1, MDM2, TP53
189.1AKT1, MDM2, TP53
19
Show member pathways
9.1AKT1, MDM2, TP53
209.1AKT1, MDM2, TP53
219.1AKT1, MDM2, TP53
22
Show member pathways
9.1AKT1, MDM2, TP53
23
Show member pathways
9.1AKT1, MDM2, TP53
24
Show member pathways
9.1AKT1, MDM2, TP53
25
Show member pathways
9.1AKT1, MDM2, TP53
269.1AKT1, MDM2, TP53
279.1AKT1, MDM2, TP53
28
Show member pathways
9.1AKT1, MDM2, TP53
299.1AKT1, MDM2, TP53
309.1AKT1, MDM2, TP53
31
Show member pathways
9.1AKT1, MDM2, TP53
329.1AKT1, MDM2, TP53
339.1AKT1, MDM2, TP53
34
Show member pathways
9.1AKT1, MDM2, TP53
358.7AKT1, CDKN2A, MDM2, TP53
36
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
37
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
38
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
39
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
40
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
41
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
428.7AKT1, CDKN2A, MDM2, TP53
43
Show member pathways
8.7AKT1, CDKN2A, MDM2, TP53
448.6CDKN2A, MCM5, MDM2, TP53
45
Show member pathways
8.6CDKN2A, MCM5, MDM2, TP53

GO Terms for genes affiliated with Anal Squamous Cell Carcinoma

About this section

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleolusGO:00057309.2CDKN2A, MDM2, TP53

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apoptotic mitochondrial changesGO:000863710.0AKT1, CDKN2A
2replicative senescenceGO:00903999.8CDKN2A, TP53
3cellular response to growth factor stimulusGO:00713639.6AKT1, MDM2
4protein complex assemblyGO:00064619.5MDM2, TP53
5negative regulation of apoptotic processGO:00430668.8AKT1, MDM2, TP53

Sources for Anal Squamous Cell Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet